Business Standard

Brokerages downgrade Divi's Labs post Q2 letdown; stock falls 11% in 2 days

EBITDA margins declined 767 bps YoY to 33.5 per cent due to high energy and transport costs.

pharma, labs, research, medical, healthcare
Premium

Photo: Bloomberg

SI Reporter Mumbai
Shares of Divi’s Laboratories hit a 52-week low of Rs 3,344.60, down 2 per cent on the BSE in Wednesday’s intra-day trade. In past two days, the stock of pharmaceuticals company has cracked 11 per cent after it reported a disappointing set of numbers with consolidated profit after tax (PAT) down 18 per cent year-on-year (YoY) and 30 per cent quarter-on-quarter (QoQ) at Rs 493.60 crore for the September quarter.

Divi’s Lab’s revenue from operations during the quarter under review de-grew 6.7 per cent YoY and 17.8 per cent QoQ at Rs 1,854 crore. Analysts expected profit of around

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 09 2022 | 9:52 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com